DOCSLIB.ORG

Cam41996 Am.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cam41996 Am.Pdf Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women RUNNING TITLE: Genetic association with variants in the vitamin D pathway KEYWORDS: ovarian cancer, genetic association, vitamin D pathway, African ancestry risk Delores J. Grant1, Ani Manichaikul2, Anthony J. Alberg3, Elisa V. Bandera4, Jill Barnholtz-Sloan5, Melissa Bondy6, Michele L. Cote7, Ellen Funkhouser8, Patricia G. Moorman9, Lauren C. Peres2, Edward S. Peters10, Ann G. Schwartz7, Paul D. Terry11, Xin-Qun Wang2, Temitope O. Keku12, Cathrine Hoyo13, Andrew Berchuck14, Dale P. Sandler15, Jack A. Taylor15, Katie M. O’Brien16, Digna R. Velez Edwards17, Todd L. Edwards18, Alicia Beeghly-Fadiel19, Nicolas Wentzensen20, Celeste Leigh Pearce21,22, Anna H. Wu22, Alice S. Whittemore23,24, Valerie McGuire23, Weiva Sieh25,26, Joseph H. Rothstein25,26, Francesmary Modugno27,28,29, Roberta Ness30, Kirsten Moysich31, Mary Anne Rossing32,33, Jennifer A. Doherty34, Thomas A. Sellers35, Jennifer B. Permuth-Way35, Alvaro N. Monteiro35, Douglas A. Levine36,37, Veronica Wendy Setiawan38, Christopher A. Haiman38, Loic LeMarchand39, Lynne R. Wilkens40, Beth Y. Karlan41, Usha Menon42, Susan Ramus43,44, Simon Gayther45,46, Aleksandra Gentry-Maharaj42, Kathryn L. Terry47,48, Daniel W. Cramer47,48, Ellen L. Goode49, Melissa C. Larson50, Scott H. Kaufmann51, Rikki Cannioto52, Kunle Odunsi53, John L. Etter31, Ruea-Yea Huang54, Marcus Q. Bernardini55, Alicia A. Tone55, Taymaa May55, Marc T. Goodman56,57, Pamela J. Thompson56, Michael E. Carney58, Shelley S. Tworoger59, Elizabeth M. Poole60, Diether Lambrechts61,62, Ignace Vergote63, Adriaan Vanderstichele63, Els Van Nieuwenhuysen63, Hoda Anton-Culver64, Argyrios Ziogas65, James D. Brenton66, Line Bjorge67,68, Helga B. Salvensen67,68, Lambertus A. Kiemeney69, Leon F. A. G. Massuger70, Tanja Pejovic71,72, Amanda Bruegl71,72, Melissa Moffitt71,72, Linda Cook73, Nhu D. Le74, Angela Brooks-Wilson75,76, Linda Kelemen77, Paul D. P. Pharoah78, Honglin Song79, Ian Campbell80,81, Diana Eccles82, Anna DeFazio83,84, Catherine J. Kennedy83,84, Joellen M. Schildkraut85 1. Department of Biological and Biomedical Sciences, Cancer Research Program, JLC- Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina, USA 2. Center for PublicAuthor Manuscript Health Genomics, University of Virginia, Charlottesville, Virginia, USA This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/CAM4.1996 This article is protected by copyright. All rights reserved 3. Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA 4. Department of Population Science, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA 5. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA 6. Cancer Prevention and Population Sciences Program, Baylor College of Medicine, Houston, Texas, USA 7. Department of Oncology and the Karmanos Cancer Institute Population Studies and Disparities Research Program, Wayne State University School of Medicine, Detroit, Michigan, USA 8. Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA 9. Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina, USA 10. Epidemiology Program, Louisiana State University Health Sciences Center School of Public Health, New Orleans, Louisisana, USA 11. Department of Medicine, University of Tennessee Medical Center – Knoxville, Knoxville, Tennessee, USA 12. Departments of Medicine and Nutrition, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA 13. Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina, USA 14. Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA 15. Epidemiology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA 16. Biostatistics and Compulational Biology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA 17. Vanderbilt Epidemiology Center, Center for Human Genetics Research, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee, USA 18. Division of Epidemiology, Center for Human Genetics Research, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA 19. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Institute for Medicine andAuthor Manuscript Public Health, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA 20. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA This article is protected by copyright. All rights reserved 21. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA 22. Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA 23. Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA 24. Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California, USA 25. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA 26. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA 27. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 28. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA 29. Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA 30. The University of Texas School of Public Health, Houston, Texas, USA 31. Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 32. Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA 33. Department of Epidemiology, University of Washington, Seattle, Washington, USA 34. Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA 35. Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA 36. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA 37. Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, New York University Langone Medical Center, New York, New York, USA 38. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA 39. University of Hawaii Cancer Center, Honolulu, Hawaii, USA 40. Cancer EpidemiologyAuthor Manuscript Program, University of Hawaii Cancer Center, Hawaii, USA 41. Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA This article is protected by copyright. All rights reserved 42. Department of Women’s Cancer, Institute for Women's Health, University College London, London, UK 43. School of Women's and Children's Health, University of New South Wales, New South Wales, Australia 44. The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia 45. Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA 46. Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA 47. Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts, USA 48. Harvard T. H. Chan School of Public Health, Boston, Massauchusetts, USA 49. Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA 50. Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA 51. Departments of Medicine and Pharmacology, Mayo Clinic, Rochester, Minnesota, USA 52. Cancer Pathology & Prevention, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, New York, USA 53. Department of Gynecological Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA 54. Center For Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, USA 55. Division of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada 56. Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA 57.
Load more

Recommended publications
  • Contig Protein Description Symbol Anterior Posterior Ratio
    Table S2. List of proteins detected in anterior and posterior intestine pooled samples. Data on protein expression are mean ± SEM of 4 pools fed the experimental diets. The number of the contig in the Sea Bream Database (http://nutrigroup-iats.org/seabreamdb) is indicated. Contig Protein Description Symbol Anterior Posterior Ratio Ant/Pos C2_6629 1,4-alpha-glucan-branching enzyme GBE1 0.88±0.1 0.91±0.03 0.98 C2_4764 116 kDa U5 small nuclear ribonucleoprotein component EFTUD2 0.74±0.09 0.71±0.05 1.03 C2_299 14-3-3 protein beta/alpha-1 YWHAB 1.45±0.23 2.18±0.09 0.67 C2_268 14-3-3 protein epsilon YWHAE 1.28±0.2 2.01±0.13 0.63 C2_2474 14-3-3 protein gamma-1 YWHAG 1.8±0.41 2.72±0.09 0.66 C2_1017 14-3-3 protein zeta YWHAZ 1.33±0.14 4.41±0.38 0.30 C2_34474 14-3-3-like protein 2 YWHAQ 1.3±0.11 1.85±0.13 0.70 C2_4902 17-beta-hydroxysteroid dehydrogenase 14 HSD17B14 0.93±0.05 2.33±0.09 0.40 C2_3100 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 ABHD5 0.85±0.07 0.78±0.13 1.10 C2_15440 1-phosphatidylinositol phosphodiesterase PLCD1 0.65±0.12 0.4±0.06 1.65 C2_12986 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta-1 PLCD1 0.76±0.08 1.15±0.16 0.66 C2_4412 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2 PLCG2 1.13±0.08 2.08±0.27 0.54 C2_3170 2,4-dienoyl-CoA reductase, mitochondrial DECR1 1.16±0.1 0.83±0.03 1.39 C2_1520 26S protease regulatory subunit 10B PSMC6 1.37±0.21 1.43±0.04 0.96 C2_4264 26S protease regulatory subunit 4 PSMC1 1.2±0.2 1.78±0.08 0.68 C2_1666 26S protease regulatory subunit 6A PSMC3 1.44±0.24 1.61±0.08
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Rats and Axolotls Share a Common Molecular Signature After Spinal Cord Injury Enriched in Collagen-1
    Rats and axolotls share a common molecular signature after spinal cord injury enriched in collagen-1 Athanasios Didangelos1, Katalin Bartus1, Jure Tica1, Bernd Roschitzki2, Elizabeth J. Bradbury1 1Wolfson CARD King’s College London, United Kingdom. 2Centre for functional Genomics, ETH Zurich, Switzerland. Running title: spinal cord injury in rats and axolotls Correspondence: A Didangelos: [email protected] SUPPLEMENTAL FIGURES AND LEGENDS Supplemental Fig. 1: Rat 7 days microarray differentially regulated transcripts. A-B: Protein-protein interaction networks of upregulated (A) and downregulated (B) transcripts identified by microarray gene expression profiling of rat SCI (4 sham versus 4 injured spinal cord samples) 7 days post-injury. Microarray expression data and experimental information is publicly available online (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45006) and is also summarised in Supplemental Table 1. Protein-protein interaction networks were performed in StringDB using the full range of protein interaction scores (0.15 – 0.99) to capture maximum evidence of proteins’ interactions. Networks were then further analysed for betweeness centrality and gene ontology (GO) annotations (BinGO) in Cytoscape. Node colour indicates betweeness centrality while edge colour and thickness indicate interaction score based on predicted functional links between nodes (green: low values; red: high values). C-D: The top 10 upregulated (C) or downregulated (D) transcripts sorted by betweeness centrality score in protein-protein interaction networks shown in A & B. E-F: Biological process GO analysis was performed on networks of upregulated and downregulated genes using BinGO in Cytoscape. Graphs indicate the 20 most significant GO categories and the number of genes in each category.
    [Show full text]
  • Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics
    ORIGINAL RESEARCH published: 03 February 2017 doi: 10.3389/fphar.2017.00023 Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard-Bock and Chantal Guillemette * Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, QC, Canada The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) significantly influences the bioavailability and biological responses of endogenous molecule substrates and xenobiotics including drugs. UGTs participate in the regulation of cellular homeostasis by limiting stress induced by toxic molecules, and by Edited by: controlling hormonal signaling networks. Glucuronidation is highly regulated at genomic, Yuji Ishii, transcriptional, post-transcriptional and post-translational levels. However, the UGT Kyushu University, Japan protein interaction network, which is likely to influence glucuronidation, has received Reviewed by: little attention. We investigated the endogenous protein interactome of human UGT1A Ben Lewis, Flinders University, Australia enzymes in main drug metabolizing non-malignant tissues where UGT expression is Shinichi Ikushiro, most prevalent, using an unbiased proteomics approach. Mass spectrometry analysis Toyama Prefectural University, Japan of affinity-purified UGT1A enzymes and associated protein complexes in liver,
    [Show full text]
  • PHASE II DRUG METABOLIZING ENZYMES Petra Jancovaa*, Pavel Anzenbacherb,Eva Anzenbacherova
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Jun; 154(2):103–116. 103 © P. Jancova, P. Anzenbacher, E. Anzenbacherova PHASE II DRUG METABOLIZING ENZYMES Petra Jancovaa*, Pavel Anzenbacherb, Eva Anzenbacherovaa a Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic b Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc E-mail: [email protected] Received: March 29, 2010; Accepted: April 20, 2010 Key words: Phase II biotransformation/UDP-glucuronosyltransferases/Sulfotransferases, N-acetyltransferases/Glutathione S-transferases/Thiopurine S-methyl transferase/Catechol O-methyl transferase Background. Phase II biotransformation reactions (also ‘conjugation reactions’) generally serve as a detoxifying step in drug metabolism. Phase II drug metabolising enzymes are mainly transferases. This review covers the major phase II enzymes: UDP-glucuronosyltransferases, sulfotransferases, N-acetyltransferases, glutathione S-transferases and methyltransferases (mainly thiopurine S-methyl transferase and catechol O-methyl transferase). The focus is on the presence of various forms, on tissue and cellular distribution, on the respective substrates, on genetic polymorphism and finally on the interspecies differences in these enzymes. Methods and Results. A literature search using the following databases PubMed, Science Direct and EBSCO for the years, 1969–2010. Conclusions. Phase II drug metabolizing enzymes play an important role in biotransformation of endogenous compounds and xenobiotics to more easily excretable forms as well as in the metabolic inactivation of pharmacologi- cally active compounds. Reduced metabolising capacity of Phase II enzymes can lead to toxic effects of clinically used drugs. Gene polymorphism/ lack of these enzymes may often play a role in several forms of cancer.
    [Show full text]
  • Endogenous Protein Interactome of Human
    Human UGT1A interaction network 1 Endogenous protein interactome of human UDP- 2 glucuronosyltransferases exposed by untargeted proteomics 3 4 5 Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard- 6 Bock and Chantal Guillemette* 7 8 Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Centre 9 Hospitalier Universitaire (CHU) de Québec Research Center and Faculty of Pharmacy, Laval 10 University, G1V 4G2, Québec, Canada 11 12 13 14 15 *Corresponding author: 16 Chantal Guillemette, Ph.D. 17 Canada Research Chair in Pharmacogenomics 18 Pharmacogenomics Laboratory, CHU de Québec Research Center, R4720 19 2705 Boul. Laurier, Québec, Canada, G1V 4G2 20 Tel. (418) 654-2296 Fax. (418) 654-2298 21 E-mail: [email protected] 22 23 24 25 26 27 28 29 30 31 32 Running title: Human UGT1A interaction network 33 1 Human UGT1A interaction network 1 Number of: Pages: 26 2 Tables: 2 3 Figures: 5 4 References: 62 5 Supplemental Tables: 7 6 Supplemental Figures: 5 7 8 Number of words: Total: 7882 9 Abstract: 229 10 Introduction: 549 11 Results: 1309 12 Discussion: 1403 13 Body Text: 3261 14 15 16 17 18 Abbreviations: AP: affinity purification; UGT, UDP-glucuronosyltransferases; IP, immuno- 19 precipitation; PPIs, protein-protein interactions; UDP-GlcA, Uridine diphospho-glucuronic acid; 20 ER, endoplasmic reticulum; MS, mass spectrometry. 21 22 Keywords: UGT; Proteomics; Protein-protein interaction; Affinity purification; Mass 23 spectrometry; Metabolism; Human tissues; 24 2 Human UGT1A interaction network 1 ABSTRACT 2 3 The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) 4 significantly influences the bioavailability and biological responses of endogenous molecule 5 substrates and xenobiotics including drugs.
    [Show full text]
  • A Systematic Analysis of a Mi-RNA Inter-Pathway Regulatory Motif Stefano Di Carlo1*†, Gianfranco Politano1†, Alessandro Savino2† and Alfredo Benso1,2†
    Di Carlo et al. Journal of Clinical Bioinformatics 2013, 3:20 JOURNAL OF http://www.jclinbioinformatics.com/content/3/1/20 CLINICAL BIOINFORMATICS RESEARCH Open Access A systematic analysis of a mi-RNA inter-pathway regulatory motif Stefano Di Carlo1*†, Gianfranco Politano1†, Alessandro Savino2† and Alfredo Benso1,2† Abstract Background: The continuing discovery of new types and functions of small non-coding RNAs is suggesting the presence of regulatory mechanisms far more complex than the ones currently used to study and design Gene Regulatory Networks. Just focusing on the roles of micro RNAs (miRNAs), they have been found to be part of several intra-pathway regulatory motifs. However, inter-pathway regulatory mechanisms have been often neglected and require further investigation. Results: In this paper we present the result of a systems biology study aimed at analyzing a high-level inter-pathway regulatory motif called Pathway Protection Loop, not previously described, in which miRNAs seem to play a crucial role in the successful behavior and activation of a pathway. Through the automatic analysis of a large set of public available databases, we found statistical evidence that this inter-pathway regulatory motif is very common in several classes of KEGG Homo Sapiens pathways and concurs in creating a complex regulatory network involving several pathways connected by this specific motif. The role of this motif seems also confirmed by a deeper review of other research activities on selected representative pathways. Conclusions: Although previous studies suggested transcriptional regulation mechanism at the pathway level such as the Pathway Protection Loop, a high-level analysis like the one proposed in this paper is still missing.
    [Show full text]
  • Glycomic and Transcriptomic Response of GSC11 Glioblastoma Stem Cells to STAT3 Phosphorylation Inhibition and Serum- Induced Differentiation
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/41720955 Glycomic and Transcriptomic Response of GSC11 Glioblastoma Stem Cells to STAT3 Phosphorylation Inhibition and Serum- Induced Differentiation Article in Journal of Proteome Research · March 2010 Impact Factor: 4.25 · DOI: 10.1021/pr900793a · Source: PubMed CITATIONS READS 21 107 11 authors, including: Yongjie Ji Waldemar Priebe University of Texas MD Anderson Cancer C… University of Texas MD Anderson Cancer C… 14 PUBLICATIONS 550 CITATIONS 275 PUBLICATIONS 6,260 CITATIONS SEE PROFILE SEE PROFILE Frederick F Lang Charles A Conrad University of Texas MD Anderson Cancer C… University of Texas MD Anderson Cancer C… 254 PUBLICATIONS 10,474 CITATIONS 84 PUBLICATIONS 2,169 CITATIONS SEE PROFILE SEE PROFILE Available from: Frederick F Lang Retrieved on: 26 May 2016 Glycomic and Transcriptomic Response of GSC11 Glioblastoma Stem Cells to STAT3 Phosphorylation Inhibition and Serum-Induced Differentiation Huan He,†,‡ Carol L. Nilsson,*,†,# Mark R. Emmett,†,‡ Alan G. Marshall,†,‡ Roger A. Kroes,§ Joseph R. Moskal,§ Yongjie Ji,| Howard Colman,| Waldemar Priebe,⊥ Frederick F. Lang,| and Charles A. Conrad| Ion Cyclotron Resonance Program, National High Magnetic Field Laboratory, Florida State University, Tallahassee, Florida 32310, Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida 32306-43903, Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois 60201, Department of Neuro-oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, and Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030 Received September 05, 2009 A glioblastoma stem cell (GSC) line, GSC11, grows as neurospheres in serum-free media supplemented with EGF (epidermal growth factor) and bFGF (basic fibroblast growth factor), and, if implanted in nude mice brains, will recapitulate high-grade glial tumors.
    [Show full text]
  • Straightjacket/Α2δ3 Deregulation Is Associated with Cardiac Conduction Defects in Myotonic Dystrophy Type 1
    bioRxiv preprint doi: https://doi.org/10.1101/431569; this version posted October 2, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Straightjacket/α2δ3 deregulation is associated with cardiac conduction defects in Myotonic Dystrophy type 1 Emilie Plantié1, Masayuki Nakamori2, Yoan Renaud3, Aline Huguet4, Caroline Choquet5, Cristiana Dondi1, Lucile Miquerol5, Masanori Takahashi6, Geneviève Gourdon4, Guillaume Junion1, Teresa Jagla1, Monika Zmojdzian1* and Krzysztof Jagla1* 1 GReD, CNRS UMR6293, INSERM U1103, University of Clermont Auvergne, 28, Place Henri Dunant, 63000 Clermont-Ferrand, France 2 Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan 3 BYONET (www.byonet.fr) 4 Imagine Institute, Inserm UMR1163, 24, boulevard de Montparnasse, 75015 Paris, France 5 Aix-Marseille University, CNRS UMR7288, IBDM Luminy Campus Case 907, 13288 Marseille cedex 9, France 6 Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan • Correspondence to: Krzysztof Jagla [email protected] and Monika Zmojdzian [email protected] tel. +33 473178181; GReD, CNRS UMR6293, INSERM U1103, University of Clermont Auvergne, 28, Place Henri Dunant, 63000 Clermont-Ferrand, France 1 bioRxiv preprint doi: https://doi.org/10.1101/431569; this version posted October 2, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Cardiac conduction defects decrease life expectancy in myotonic dystrophy type 1 (DM1), a complex toxic CTG repeat disorder involving misbalance between two RNA- binding factors, MBNL1 and CELF1.
    [Show full text]
  • Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes in Vitro
    molecules Article Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes In Vitro Hassan Salhab * , Declan P. Naughton and James Barker School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston-Upon-Thames, London KT1 2EE, UK; [email protected] (D.P.N.); [email protected] (J.B.) * Correspondence: [email protected]; Tel.: +44-7984974741; Fax: +44-208-4179000 Abstract: Glucuronidation is a Phase 2 metabolic pathway responsible for the metabolism and excretion of testosterone to a conjugate testosterone glucuronide. Bioavailability and the rate of anabolic steroid testosterone metabolism can be affected upon UGT glucuronidation enzyme alter- ation. However, there is a lack of information about the in vitro potential assessment of UGT2B17 inhibition by salicylic acid. The purpose of this study is to investigate if UGT2B17 enzyme activity is inhibited by salicylic acid. A UGT2B17 assay was developed and validated by HPLC using a C18 reversed phase column (SUPELCO 25 cm × 4.6 mm, 5 µm) at 246 nm using a gradient elution mobile phase system: (A) phosphate buffer (0.01 M) at pH = 3.8, (B) HPLC grade acetonitrile and (C) HPLC grade methanol. The UGT2B17 metabolite (testosterone glucuronide) was quantified using human UGT2B17 supersomes by a validated HPLC method. The type of inhibition was determined by Lineweaver–Burk plots. These were constructed from the in vitro inhibition of salicylic acid at different concentration levels. The UGT2B17 assay showed good linearity (R2 > 0.99), acceptable recovery and accuracy (80–120%), good reproducibility and acceptable inter and intra-assay precision Citation: Salhab, H.; Naughton, D.P.; (<15%), low detection (6.42 and 2.76 µM) and quantitation limit values (19.46 and 8.38 µM) for Barker, J.
    [Show full text]
  • Kidney V-Atpase-Rich Cell Proteome Database
    A comprehensive list of the proteins that are expressed in V-ATPase-rich cells harvested from the kidneys based on the isolation by enzymatic digestion and fluorescence-activated cell sorting (FACS) from transgenic B1-EGFP mice, which express EGFP under the control of the promoter of the V-ATPase-B1 subunit. In these mice, type A and B intercalated cells and connecting segment principal cells of the kidney express EGFP. The protein identification was performed by LC-MS/MS using an LTQ tandem mass spectrometer (Thermo Fisher Scientific). For questions or comments please contact Sylvie Breton ([email protected]) or Mark A. Knepper ([email protected]).
    [Show full text]
  • Studies on Bilirubin and Steroid Glucuronidation
    Centre for Drug research Division of Pharmaceutical Chemistry Faculty of Pharmacy University of Helsinki Finland UDP-GLUCURONOSYLTRANSFERASES IN SICKNESS AND HEALTH STUDIES ON BILIRUBIN AND STEROID GLUCURONIDATION Nina Sneitz ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Pharmacy of the University of Helsinki, for public examination in Auditorium 1, Korona Information Centre, on 25 October 2013, at 12 noon. Helsinki 2013 Supervisor: Dr. Moshe Finel Centre for Drug Research (CDR) Faculty of Pharmacy University of Helsinki Finland Reviewers: Professor Peter Mackenzie Department of Clinical Pharmacology School of Medicine Flinders University Australia Professor Hannu Raunio Faculty of Health Sciences School of Pharmacy University of Eastern Finland Finland Opponent: Professor Philip Lazarus Department of Pharmaceutical Sciences College of Pharmacy Washington State University College of Pharmacy USA © Nina Sneitz 2013 ISBN 978-952-10-9292-3 (Paperback) ISBN 978-952-10-9293-0 (PDF) ISSN 1799-7372 http://ethesis.helsinki.fi/ Helsinki University Printing House Helsinki 2013 CONTENTS Abstract 5 Acknowledgements 7 List of original publications 8 Abbreviations 9 1 Introduction 10 2 Review of the Literature 12 2.1 UDP-glucuronosyltransferases in brief 12 2.2 Bilirubin metabolism and Familial hyperbilirubinemias 15 2.2.1 Bilirubin: properties and metabolism 15 2.2.2 Gilbert syndrome 17 2.2.3 Crigler-Najjar syndromes 18 2.2.3.1 Current therapy for Crigler-Najjar syndrome 20 2.2.3.2 Gene therapy in treatment of Crigler-Najjar syndrome 20 2.3 Steroid hormones and their metabolism 22 2.3.1 Glucuronidation of steroid hormones 24 2.3.2 Steroids and health 26 2.4 Steroid glucuronidation and UGT structure 28 3 Aims of the study 30 4 Materials and Methods 31 4.1 Materials 31 4.1.1.
    [Show full text]